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The aim of this study is to assess the long-term effect of mesenchymal stem cells (MSC) transplantation in
a rat model of chronic myocardial infarction (MI) in comparison with the effect of bone marrow mononu-
clear cells (BM-MNC) transplant. Five weeks after induction of MI, rats were allocated to receive intramyo-
cardial injection of 106 GFP-expressing cells (BM-MNC or MSC) or medium as control. Heart function
(echocardiography and 18F-FDG-microPET) and histological studies were performed 3 months after trans-
plantation and cell fate was analyzed along the experiment (1 and 2 weeks and 1 and 3 months). The main
findings of this study were that both BM-derived populations, BM-MNC and MSC, induced a long-lasting
(3 months) improvement in LVEF (BM-MNC: 26.61 ± 2.01% to 46.61 ± 3.7%, p < 0.05; MSC: 27.5 ±
1.28% to 38.8 ± 3.2%, p < 0.05) but remarkably, only MSC improved tissue metabolism quantified by 18F-
FDG uptake (71.15 ± 1.27 to 76.31 ± 1.11, p < 0.01), which was thereby associated with a smaller infarct size
and scar collagen content and also with a higher revascularization degree. Altogether, results show that MSC
provides a long-term superior benefit than whole BM-MNC transplantation in a rat model of chronic MI.
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INTRODUCTION the potential for improvement in cardiac function. Dif-
ferent cell types (51) have been employed in animal
models [reviewed in (53)] with, importantly, bone mar-Cardiovascular diseases are a leading health concern
in Western countries (40), with ischemia as the main row-mononuclear cells (BM-MNC) (37), mesenchymal
stem cells (21), and skeletal myoblasts undergoing clini-mechanism for loss of cardiomyocyte (CM) mass and
contractile force. In spite of new approaches and thera- cal trials (3,35,42,45). Although animal studies and
phase I studies suggested a positive effect of these cellpies (9,22,25,26,34,39,57), regeneration of the damaged
tissue has not been successfully achieved, and compen- populations, recently published randomized clinical tri-
als have shown controversial results (42,43). Althoughsation of chronic hypertrophy is in most cases difficult,
leaving heart transplantation as the only alternative for new long-term studies with larger patient groups are re-
quired in order to confirm these data, the use of otherend-stage patients.
Stem cell application to the field of regenerative med- cell types that could offer better chances to regenerate
the infarcted heart may be a useful approach.icine offers new strategies to induce tissue repair and
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Bone marrow has been shown to contain several pop- Characterization of MSC was performed by FACS and
differentiation capacity. Cells were stained with antibod-ulations of stem cells like hematopoietic stem cells, en-
dothelial progenitor cells, mesenchymal stem cells (MSC) ies against RT1A, RT1B, CD31, CD44, CD45, CD73,
and CD90 (all purchased from BD, Madrid, Spain). For[reviewed in (32)], and others with greater differentia-
tion capacity like the multipotent adult progenitor cells osteogenic differentiation, cells were plated at 6000
cells/cm2 in osteogenic media [αMEM with 10% FCS,(MAPC) (24), the marrow-isolated multilineage induc-
ible (MIAMI) cells (13), or the very small embryonic- 1% antibiotics, 10 mM β-glicerolphosphate (Sigma), 0.2
mM ascorbate-2-phosphate (Sigma), and 0.01 µM dexa-like (VSEL) cells (30). While the product obtained from
a bone marrow aspiration contains some of these pro- methasone (Sigma)]. Condrogenic differentiation was
performed with 200,000 pelleted cells suspended in con-genitors, their proportion might be too low to exert any
significant benefit in the setting of cardiac ischemia. It drogenic media [DMEM-high glucose (Invitrogen) with
1% antibiotics, 10 ng/ml TGF-β3 (R&D Systems, Min-is thus logical to believe that enrichment of some of
these populations in vitro could enhance the beneficial neapolis, MN, USA), 50 mg/ml ITS+Premix (BD), 40
µg/ml proline (Sigma), 500 ng/ml BMP6 (R&D Sys-effects of BM-MNC transplantation. On the other hand,
MSC have attracted much attention in the field given tems), 50 µg/ml ascorbate-2-P, and 0.1 µM dexametha-
sone]. For adipogenic differentiation, when cells reachedtheir potential to transdifferentiate into suitable pheno-
types (17,19,36) and also to exert paracrine actions upon 95–100% confluence, expansion media was replaced
with adipogenic media [αMEM with 10% FCS, 1% an-the ischemic tissues (29,38). Moreover, their immuno-
modulatory properties (31) could exert a positive effect tobiotics, 50 µM indomethacin (Sigma), 0.5 mM IBMX
(Sigma), and 1 µM dexamethasone]. All differentiationafter transplantation into the heart by regulation of tissue
inflammation (4). On top of this, their in vitro process- protocols were maintained for 21 days. Analysis of cell
differentiation was performed by histochemical staininging is simple and even in humans renders sufficient
amount of cells for an optimum treatment of the disease. by Oil red O (adipogenic), Alizarin red (osteogenic), and
toluidine blue (condrogenic) following previously de-Currently, although many studies have been per-
formed with different stem cell preparations in myocar- scribed protocols (62).
dial ischemia models, the lack of comparative studies
Experimental Modelmakes it difficult to determine which population has a
better regenerative effect. Moreover, bone marrow-de- A total of 115 female Sprague-Dawley rats (Harlan
IBERICA S.L. Barcelona, Spain) underwent coronaryrived stem cells have been mainly tested in acute models
of myocardial infarction. Thus, in the current study we artery ligation of the left coronary artery as previously
described (3). Only those animals that survived (n = 97)sought to compare the long-term putative beneficial ef-
fects of two stem cell populations derived from the BM: and with a LVEF below 40% at 1 month post-MI were
included in the study (n = 75). Five weeks after myocar-freshly isolated BM-MNC and bone marrow MSC in a
chronic model of myocardial infarction. dial infarction induction, rats were reoperated by sterno-
tomy and allocated to receive 106 cells per animal (total
MATERIALS AND METHODS volume: 70 µl) of BM-MNC (n = 24), MSC (n = 25), or
control medium (n = 26) in two points of the infarct bor-
Isolation and Characterization of Cells der region. Due to the allogeneic origin of the cells, ani-
mals were daily immune-suppressed with cyclosporin AAll eGFP cells (bone marrow) were isolated from
4–6-week-old Sprague-Dawley eGFP rats. Bone mar- (20 mg/kg/day, IP, Sandimmun, Novartis) from 2 days
pretransplantation until sacrifice. Rate of survival overrow cells were harvested from rat femurs and isolated
by means of a Ficoll-Paque density gradient centrifuga- the course of the experiment was over 98%. All experi-
ments, including bone marrow cell isolation, were per-tion. For BM-MNC transplantation, cells were washed
and resuspended in culture media (DMEM, Invitrogen, formed in accordance with the principles of laboratory
animal care formulated by the National Society for Med-Leiden, The Netherlands) without supplements at a con-
centration of 106 cells in 70 µl. Viability by trypan blue ical Research and the guide for the care and use of labo-
ratory animals by the Institute of Laboratory Animaldye exclusion was shown to be above 98%.
MSC were obtained from mononuclear cells. Briefly, Resources (Commission on Life Science, National Re-
search Council). All animal procedures were approvedcells were seeded at 50,000 cells/cm2 in αMEM (In-
vitrogen) with 10% fetal calf serum (FCS, Cambrex, Mi- by the University of Navarra Institutional Committee on
Care and Use of Laboratory Animals.lano, Italy), 1% penicillin/streptomycin, and 10 ng/ml
bFGF (Sigma, Madrid, Spain) and maintained in a hu-
Tissue Processing and Stainingmidified atmosphere in 5% CO2. Subconfluent MSC
were obtained within a week and passed at 5000 cells/ For histological analysis, three animals per group
were sacrificed at 1, 2, and 4 weeks, respectively andcm2. Cells were used for transplant after five passages.
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eight animals per group at 3 months. After sacrifice, rat stained lightly with 1% toluidine blue. Later ultrathin
(0.05 µm) sections were cut with a diamond knife,hearts were excised, fixed in 4% paraformaldehyde for
4 h at 4°C, and cut in three equal size blocks (apical, stained with lead citrate, and examined under a Fei Tec-
nai spirit electron microscopy. Over 15 samples per ani-midventricular, and basal). Hearts were either dehy-
drated in ethanol 70% (4°C o/n) and embedded in paraf- mal were analyzed.
fin or saturated in 25% sucrose (4°C o/n), embedded in
Morphometric AnalysisO.C.T. compound, and snap frozen in nitrogen-cooled
isopentane. For histological analysis 5-µm sections were Quantification of vascular density was performed in
animals sacrificed 3 months posttransplantation. Forcut. Cell detection was based upon the presence of GFP-
positive signals by inmunohistochemical [anti-GFP capillary density (capillaries/mm2), a total of 15 serial
sections including the infarct area, 30 µm apart, werepolyclonal Ab (pAb, Invitrogen) or anti-GFP raised in
chicken pAb (Abcam, Cambridge, UK) diluted 1:500 stained with caveolin-1 and a total of 30 infarct border
images were analyzed. Arteriolar density (arterioles/in TBS] or immunofluorescence methods. For immuno-
fluorescence, a tyramide amplifying kit (Invitrogen) or mm2) and arteriolar area (µm2) were quantified in a simi-
lar way after staining with anti-α-SMA-Cy3 in the fol-a secondary antibody anti-chicken IgY coupled to 655
nm emitting quantum dots were used following manu- lowing sections. Pictures were taken on a Nikon Eclipse
E800 microscope equipped with epifluorescence opticsfacturer’s instructions. Immunolabeling was performed
with antibodies against α-smooth muscle actin (α-SMA) and digital images were analyzed using imaging soft-
ware (Jay Image), or on a Zeiss LSM 510 META laser[mouse monoclonal antibody (mAb) diluted 1:1000 in
TBS; Sigma, Madrid, Spain] coupled to Cy3, cardiac confocal microscope. The degree of fibrosis was deter-
mined by quantification of collagen deposition stainedtroponin T (cTT) (mAb, diluted 1:100 in TBS; Labvi-
sion), ventricular myosin (mAb diluted 1:2 in TBS; Bio- by Sirius red as previously described (16). Briefly, a
mean of 15 serial sections were stained, each 30 µmCytex), Ki-67 (mAb, diluted 1:25 in TBS; DAKO, Bar-
celona, Spain), PCNA (mAb, diluted 1:100 in PBS; apart. Infarct size was assessed as the mean percent of
infarcted area versus total LV area, whereas fibrosis wasSanta Cruz), CD68 (mAb, diluted 1:200 in TBS; Sero-
tec, Oxford, UK), caveolin-1 (mAb, diluted 1:100 in measured in high-power photographs within the infarct
as percent of collagen area (red) versus total tissue areaTBS, BD), connexin 43 (pAb, diluted 1:200 in TBS,
Sigma). Secondary antibodies labeled with AlexaFluor- using AnalySISR software. Cell engraftment was quanti-
fied after GFP immunostaining. Positive cells were only594 or AlexaFluor-488 were purchased from Molecular
Probes (Invitrogen) if needed and used following the counted if their nucleus was identifiable. Tissue sections
were screened and GFP cells quantified from the first tomanufacturer’s instructions. EnVisionTM-HRP conjugated
system (Dako) was used as secondary reagent for immu- the last section with engrafted cells. This was made rela-
tive to the quantity of injected cells (106M) as the per-nohistochemistry. For nuclear staining, TOPRO-3 (di-
luted 1:50 in PBS-glycerol) for confocal microscopy or centage of surviving cells.
Macrophage density was measured as number ofDAPI (diluted 1:4 in PBS-glycerol) for conventional IF
microscopy were utilized. For confocal microscopy, a CD68-positive cells per area unit in a mean of 15 sec-
tions, each 30 µm apart. Finally, cell proliferation wasLSM 510 META (Carl Zeiss, Minneapolis, USA) micro-
scope was used. quantified in animals sacrificed 1 and 2 weeks after cell
injection by counting PCNA-positive cells in sectionsFor Sirius Red staining, sections were deparaffinized
and immersed in Sirius Red (Sigma) for 90 min, differ- stained for GFP, PCNA, and a lineage-specific marker,
either caveolin-1 for endothelium or α-SMA for myofi-entiated 2 min in HCl (Sigma) 0.01 N, dehydrated, and
mounted in DPX. Hematoxylin-eosin staining was per- broblast or smooth muscle. Number of sections was the
same as for macrophage density. All photographs wereformed as detailed elsewhere (16). Briefly, sections
where stained in Ehrlich’s hematoxylin (Sigma) for 7 taken on a Zeiss LSM 510 META laser confocal micro-
scope.min, differentiated through water-HCl and Li2CO3 solu-
tions, immersed in eosin (Sigma) for 10 s, dehydrated,
Echocardiographic Studiesand mounted in DPX.
Animals were slightly anesthetized prior to study
Electron Microscopy with 2% isoflurane (Forane, Lab. ABBOTT S.A, Ma-
drid, Spain) in 100% O2 gas and placed in the supine orFor electron microscopy studies, six to eight animals
per group were sacrificed and hearts were fixed with 4% lateral position on a warming pad for transthoracic two-
dimensional echocardiography, M-mode recordings, andparaformaldehyde 0.5% glutaraldehyde. Sections were
postfixed with 1% osmium (30 min), rinsed, dehydrated, Doppler ultrasound measurements as previously de-
scribed (3). Echocardiography was performed using aand embedded in araldite (Durcupan, Fluka). Semithin
sections (1.5 µm) were cut with a diamond knife and Sonos 4500 ultrasound system (Philips) with a 12 MHz
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linear array transducer and Doppler measurement. Left Mann-Whitney test with Finner’s correction of signifi-
cance. Shapiro-Wilk test was used to verify that the dataventricular remodeling was assessed by measuring end
systolic and diastolic volumes and diameters according had a Gaussian distribution, which justifies the use of a
parametric test. Statistical analysis was performed withto the American Society of Echocardiology. The left
ventricular ejection fraction was determined in paraster- the SPSS 11.0 software and differences were considered
statistically significant when p < 0.05.nal short axes (41) and diastolic function was assessed
by measuring E and A waves of the mitral filling pattern
RESULTSby pulsed echo-Doppler technique in four-chamber api-
cal views. Echocardiographic studies were performed at
Cell Culture and Characterizationbaseline (before infarct), before cell transplantation, and
at day 90 posttransplant by the same blinded investiga- MSC presented a typical spindle-shape in culture
conditions. GFP expression was monitored during cul-tor. Measurements were done in three cycles and the
mean value was obtained. ture and before transplantation, ensuring that over 90%
of the cells were positive (not shown). At passage 4, this
18F-FDG PET Imaging Protocols, Image population had a FACS expression profile as follows:
Reconstruction, and Semiquantitative Evaluation RT1A, CD44, CD73, and CD90 positive and RT1B,
CD31, and CD45 negative (Fig. 1A, representative histo-Immediately before injection of cells and 90 days
later, animals were subjected to PET analysis using the grams are shown). Moreover, MSC differentiated to-
wards condrogenic, adipogenic, and osteogenic lineagestechnique previously described by our group demon-
strating that 18F-FDG-micro-PET provides valuable sem- (Fig. 1B), thus proving their multipotency. BM-MNC
were obtained following previously reported protocolsiquantitative information and allow noninvasive follow-
up of heart glucose metabolism, representing a useful (48).
strategy for assessment of novel therapies in cardiac re-
Mesenchymal Cell Injection Induces ageneration (49). Rats were anesthetized with 2% isoflur-
Long-Lasting Improvement of Cardiac Functionane in 100% O2 gas and after tail vein injection of 18F-
and Tissue MetabolismFDG (75 MBq in 100–200 µl), immediately awakened,
and placed back in the cage. Two hours after tracer in- In order to assess if cell therapy was capable of in-
ducing a long-lasting improvement in a model of ratjection, animals were anesthetized with isoflurane, placed
prone on the PET scanner cradle, and kept during the chronic MI, cardiac function and tissue metabolism were
monitored by echocardiography and microPET, 3 monthsoverall study under continuous influx of the anesthetic.
A static 60-min study (sinogram) was acquired in a Mo- after injection of BM-MNC, MSC, or control media. Ar-
tery ligation provoked a marked reduction of the leftsaic (Philips) small-animal dedicated imaging tomo-
graph. Scanner efficiency normalization, dead time, and ventricular ejection fraction (LVEF) from baseline
(72.23 ± 8.47%, mean ± SD) to preinjection (5 weeksdecay corrections were applied during reconstruction.
Images were reoriented for further processing and polar later) (27.82 ± 6.69%), which did not differ between all
three groups. Compared to their preimplant values, bothmaps obtained using the specific cardiac imaging soft-
ware package of the PET scanner. After reorientation of BM-MNC and MSC treatment induced a statistically
significant improvement of left ventricular (LV) func-transaxial images into short- and long-axis slices polar
maps were generated and divided into 17 different ROIs. tion (BM-MNC: 26.61 ± 2.01% to 42.61 ± 3.7%; MSC:
27.5 ± 1.28% to 38.8 ± 3.2% pretransplant and 3 months,Individual quantification of the 18F-FDG uptake in each
of them was calculated. The total number of counts ob- respectively; p < 0.05), whereas animals injected with
medium did not show any improvement in the cardiactained for each of the ROIs was divided by its corre-
sponding area to obtain counts per area unit. For each function (29.87 ± 2.84% to 28.1 ± 1.59%) (Fig. 2). No
significant differences were detected between both cell-PET study, the maximal value of the 17 ROIs was con-
sidered as 100% and the remaining data transformed treated groups (BM-MNC vs. MSC; p = 0.97), indicat-
ing no superior benefit from one or the other cell popu-into percentage values. All further calculations and sta-
tistical analysis were performed on these sets of rescaled lation. Analysis of polar maps including the whole left
ventricle (the 17 cardiac segments) showed that MSC-numerical data.
treated animals had a significant improvement in cardiac
Statistical Analysis metabolism compared with their preinjection parameters
(72.15 ± 1.17% to 76.31 ± 1.1%; p < 0.01) (Fig. 3A).All data are expressed as mean ± SEM or median
(Q25; Q75). Comparisons for repeated measurements MSC treatment proved to have a positive effect not only
in global tissue metabolism, but more importantly whenwere performed by ANOVA accompanied by Tukey’s
HDS for intergroup comparisons or Kruskal-Wallis and the analysis was restricted to the infarcted segments (7,
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Figure 1. MSC characterization. (A) MSC were stained with antibodies against RT1B, CD31,
CD45, RT1A, CD44, CD73, and CD90 (red line) or isotype controls (dashed line). (B) MSC were
differentiated in vitro towards chondrocites (as shown by toluidine blue staining), adipocytes (Oil
red O staining), and osteocytes (Alizarin red staining). Scale bars: 25 µm.
13, 16, and 17) as depicted by the significant increase myocardium of infarcted animals, and this number de-
creased to 1.33% (0.52; 2.14) at 2 weeks, were almostin their metabolism (46.8 ± 3.35% to 53.02 ± 3.55%,
p < 0.05) (Fig. 3B, C). On the contrary, BM-MNC injec- not detectable at 1 month, and disappeared at 3 months.
On the other hand, presence of GFP-BM-MNC couldtion did not have a significant effect in tissue metabo-
lism (all segments: 70.87 ± 1.88% to 73.55 ± 1.88%; in- not be detected even at 1 week posttransplant (Fig. 4E–
H). No positive signal was found on medium-injectedfarcted segments: 44.8 ± 4.3% to 50.4 ± 4.63%).
animals (Fig. 4I–L).
MSC Engraft in the Ischemic Tissue and Induce a It is possible that, despite immunosuppression, the
Reduced Inflammatory Reaction Than BM-MNC GFP antigen could be recognized by the macrophages,
which in turn could react against the transplanted cellsCell fate was analyzed by immunohistochemical and
immunofluorescence detection of GFP-positive cells at (33). In order to study this, CD68 immunostaining was
performed in animals sacrificed 1 week after transplant.1 and 2 weeks and 1 and 3 months after their transplan-
tation in the border zone of the infarct. We found large Intra- and peri-infarct sections were analyzed and, as de-
picted in Figure 5, a strong macrophage infiltration waspatches of GFP-positive cells at the injection site in rats
treated with MSC 1 and 2 weeks after transplantation, found in BM-MNC-treated animals, both in the infarct
(327.6 ± 49.67 positive cells/mm2, p < 0.01 vs. medium)but not from 1 month onwards (Fig. 4A–D). Cell en-
graftment was quantified in MSC-treated animals as de- (Fig. 5A–D) and peri-infarct (1945.78 ± 372.08 positive
cells/mm2, p < 0.01 vs. medium) (Fig. 5E–H) regions inscribed in Materials and Methods. One week after trans-
plant, 1.85% (0.53; 3.02) [median (Q25; Q75)] of the comparison with media-injected animals (Medium, in-
tra-infarct: 94.5 ± 6.05 positive cells/mm2; peri-infarct:total number of injected cells were still present in the
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Figure 2. BM-MNC and MSC improve cardiac function. LVEF was assessed by echocardiography
before and 3 months after transplantation of BM-MNC or MSC. Cell culture medium was injected
in the control group. Results are shown as mean ± SD and statistical significance was calculated
by comparing the LVEF values 3 months after transplantation versus preimplantation, in each
group (*p < 0.05).
Figure 3. MSC positively affect tissue metabolism. 18F-FDG uptake was evaluated by microPET before and 3 months after trans-
plantation. A significant increase in the tissue metabolism was detected in the MSC-treated but not in the BM-MNC-treated hearts
when all 17 segments were analyzed (mean ± SD, **p < 0.01) (A) and also when only the infarcted ones were analyzed (*p < 0.05)
(B). Representative images (cross and longitudinal views) of the hearts, 3 months after cell or medium injection, are shown (C).
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Figure 4. Cell engraftment. Presence of transplanted cells was assessed by immunohistochemistry against GFP at 1 and 2 weeks
and 1 and 3 months after their injection. Engraftment was only detected for MSC at 1 and 2 weeks. (A–D) DMEM; (E–H) BM-
MNC; (I–L) MSC. Scale bars: 100 µm.
167.48 ± 39.91 positive cells/mm2). MSC-transplanted were detected [percentage of double positive cells: 1
week: 12.80 (7.5; 20.6); 2 weeks 9.48 (10; 20.74), me-animals did also show an increase in CD68-positive
cells, albeit significantly lower than BM-MNC (intra- dian (Q25; Q75)], these cells did not form vessel-like
structures remaining with a fibroblastic morphologyinfarct: 230.86 ± 59.27 positive cells/mm2, p < 0.01 vs.
medium; peri-infarct: 427.21 ± 71.7 positive cells/mm2; consistent with myofibroblast (Fig. 7A). Furthermore,
expression of this marker was not surprising, as MSCp < 0.01 vs. control; p < 0.01 vs. BM-MNC). The in-
crease in macrophage infiltration in the BM-MNC-trans- do express α-SMA in in vitro culture (data not shown).
Cardiac contribution could not be detected by doubleplanted animals was not due to the direct contribution
of the transplanted cells as demonstrated by the lack of staining for GFP and the cardiac markers MLC2v or
cTT (data not shown).CD68+/GFP+ cells. Furthermore, double staining for
GFP and CD68 revealed a strong infiltration of macro- In order to confirm these data and identify the pheno-
typic identity of the mesenchymal cells once trans-phages in close contact with injected MSC (Fig. 5I–M).
Presence of GFP vesicles could be detected in the in- planted, electron microscopy after preembedding immu-
nohistochemistry for GFP was performed. Four ratsflammatory cells by immunofluorescence (Fig. 5M) and
confirmed by electronic microscopy (Fig. 6), suggesting sacrificed 1 or 2 weeks after injection were studied and
a mean of 30 cells/rat were analyzed. Confirming thehost cell-mediated immune rejection of the transplanted
cells. results obtained in the immunofluorescence analysis, no
vascular or cardiac GFP-positive cells were found and
MSC Do Not Differentiate Towards Vascular or GFP-positive cells showed a typical fibroblastic pheno-
Cardiac Phenotypes In Vivo type with an elongated nucleus with a central nucleolus,
small clumps chromatin organization, and a high densityIn vivo differentiation of MSC was analyzed by dou-
ble immunofluorescence with antibodies against GFP of RER cisterns (Fig. 7B). Implanted cells also pre-
sented big dictosomes and large mitochondrias and ca-and lineage-specific markers in tissue obtained at 1 and
2 weeks posttransplant. Transplanted MSC did not colo- veoli (Fig. 7B, arrowheads) along their surface. Interest-
ingly, a consistent collagen network was found aroundcalize with endothelial markers such as caveolin-1, indi-
cating lack of differentiation to endothelium (data not them (Fig. 7B, asterisks).
On the other hand, although vascular or cardiac directshown). On the other hand, although α-SMA-GFP cells
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Figure 5. Cell transplantation in chronic MI is associated with macrophage infiltration. Sections of hearts obtained 1 and 2 weeks
and 1 and 3 months after cell or media transplant were stained with antibodies against CD68 (red) and GFP (green) and macrophage
infiltration was quantified as described in Materials and Methods. A significant (**p < 0.01) increase in macrophage density within
the infarcted area of BM-MNC-implanted but not of MSC-implanted animals was found (A–D). Also in the peri-infarct area, there
was a significant increase (**p < 0.01) in CD68-positive cell density in the peri-infarct region of BM-MNC- and MSC-treated rats,
although this was less pronounced in the MSC than in the BM-MNC group (**p < 0.01) (E–H). Detailed CD68-positive macro-
phages infiltrating MSC injection areas are shown (I–M) with detectable GFP-positive vesicles in some of the phagocytes (arrow-
heads) (M). Images correspond to animals sacrificed 1 week after cell or medium injection. CD68 marker (Alexa-594): red; GFP
(Alexa-488): green; nuclear staining (TOPRO3): blue. Scale bars: (B–D, F–H) 35 µm; (I–L) 20 µm; (M) 5 µm.
Figure 6. Electron microscopy of macrophages within cell-engrafted areas. One week after MSC transplantation, presence of
macrophages (arrowheads) was confirmed by electronic microscopy, in the areas of cell injection (collagen deposits are indicated
with asterisks) (A). A higher magnification field shows a GFP vesicle-containing macrophage. GFP deposits could be detected
after previous immunogold GFP staining (arrowheads) (B). Scale bars: (A) 6 µm; (B) 2 µm.
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Figure 7. Analysis of cell fate and in vivo proliferation. One and 2 weeks after transplant, heart sections were stained with
antibodies against α-SM-actin-Cy3 and PCNA (Alexa-594: red) and GFP (Alexa-488: green). Nuclear staining was performed with
TOPRO3 (blue). Expression of lineage-specific markers was tested by double immunofluorescence. Engrafted GFP-MSC were
positive for α-SM-actin (higher magnification field: arrowheads) although remained as myofibroblasts and did not contribute to the
vascular net (A). Proliferating GFP-positive MSC (arrowheads) were also observed surrounded by proliferating non-GFP cells
(asterisks) (B). GFP-positive cells were identified after GFP immunogold staining as fibroblast-like cells, which were surrounded
by areas of collagen deposition (asterisks). Top right: higher magnification showing a GFP-positive cell; bottom right: caveoli in
the membrane of GFP-MSC (arrowheads) (C). Images were taken from animals sacrificed 1 week after treatment. Scale bars: (A,
B) 25 µm; higher magnification (B): 10 µm; (C) 2 µm; top right: 400 nm; bottom right: 100 nm.
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contribution could not be detected, a small percentage of MSC: 897.1 ± 61.6 capillaries/mm2; p < 0.05) (Fig. 9B–
D). On the other hand, both cell treatments induced anengrafted MSC (approximately 10% of engrafted cells at
1 week) did costained with PCNA (Fig. 7C, arrow- increase in big caliber vessels, quantified as α-SMA-
positive vessels/mm2 (medium: 64.1 ± 5.4; BM-MNC:heads), indicating their ability to proliferate within the
damaged tissue. GFP cycling cells were not detected 130.1 ± 11; MSC: 145.7 ± 7.8; p < 0.01 in both cell-
treated groups vs. medium) and α-SMA-positive areaafter 2 weeks posttransplant, suggesting either that pro-
liferation occurred during a short time or that immune (medium: 1.2 ± 0.1%; BM-MNC: 2.09 ± 0.14%; MSC:
2.53 ± 0.15%; p < 0.01 in both cell-treated groups vs.rejection was involved in the lack of proliferating cells.
Interestingly, non-GFP cells located in the area of injec- medium). Importantly, such increase in arterioles/arter-
ies density in the peri-infarct region was significantlytion also expressed PCNA (Fig. 7C, asterisks), suggest-
ing an (auto)paracrine effect of the MSC that promotes higher in the animals treated with MSC than in the BM-
MNC-treated animals (p < 0.01 MSC vs. BM-MNC)cell proliferation. Although most proliferating cells were
of hematopoietic lineage (not shown), cell-implanted an- (Fig. 9E–H).
As together with the revascularization processes, tis-imals also showed a marked increase in the density of
endothelial-proliferating cells both in the peri-infarct sue remodeling may have an important role in the func-
tional benefits. We analyzed infarct size and collagenand infarct regions in the groups of animals treated with
MSC (peri-infarct: 1 week: 69.44 ± 13 cells/mm2; 2 content in the treated versus control animals and, as
shown in Figure 9I–L, MSC- but not BM-MNC-treatedweeks: 56.88 ± 5.29 cells/mm2; p < 0.01 vs. medium; in-
farct: 1 week: 100 ± 16.61 cells/mm,sup>2; 2 weeks: hearts induced a significant decrease in infarct size com-
pared to medium-injected controls (medium: 19.66 ±48.73 ± 14.13 cells/mm2; p < 0.01 vs. medium) and BM-
MNC (peri-infarct: 78.19 ± 11.26 cells/mm2; 2 weeks: 1.21%; BM-MNC: 17.47 ± 4.62%; MSC: 12.78 ± 1.66%;
p < 0.05, percentages referred to the total LV area). Fur-54.13 ± 10.99 cells/mm2; p < 0.01 vs. medium; infarct:
1 week: 42.89 ± 8.5 cells/mm2; 2 weeks: 38.27 ± 7.97 thermore, a smaller infarct was associated with a de-
crease in collagen vascular fraction (CVF) (Fig. 9M–P)cells/mm2; p < 0.01 vs. medium) (Fig. 8A). MSC-treated
hearts also presented an augmented density of cycling in MSC-injected animals (control group: 66.26 ± 0.93%;
BM-MN: 63.77 ± 8.53%; MSC: 58.54 ± 1.36%, p < 0myofibroblasts (peri-infarct: 1 week: 113.17 ± 26.57
cells/mm2; 2 weeks: 43.57 ± 10.03 cells/mm2; p < 0.01 05), showing a positive correlation between both param-
eters (R2 = 0.73, p < 0.01), thereby demonstrating the su-vs. medium; p < 0.01 vs. BM-MNC) that were rarely
found in BM-MNC-treated animals and even less in perior effect of the MSC versus the BM-MNC.
control animals. Finally, although some dividing smooth
DISCUSSIONmuscle cells were identified, their numbers were only
significantly increased in MSC-treated animals 1 week In this study, the rigorous comparison of the long-
term effect of two bone marrow derived populations,after injection (17.49 ± 6.08 cells/mm2; p < 0.05 vs. me-
dium). Representative images are shown in Figure 8B. BM-MNC and MSC, in a chronic model of myocardial
infarction indicates that transplantation of both BM stemNo proliferating endothelial cells, myofibroblasts, or
smooth muscle cells were detected 1 or 2 weeks after cell populations induced a similar functional improve-
ment but, importantly, that MSC induced a greater effectmedia injection (6 and 7 weeks after myocardial infarc-
tion) in animals treated with media alone. in the injured hearts that resulted in a smaller infarct size
and scar collagen content with an increase in revascu-
MSC Promotes Revascularization larization of the tissue. These effects eventually corre-
and Cardiac Remodeling lated with an increased tissue metabolism and a func-
tional improvement in the contractile capacity of theDespite the low engraftment rate and the lack of dif-
ferentiation, a functional benefit was detected in the rats myocardium.
Different factors might be responsible for the supe-transplanted with bone marrow-derived cells, with a
stronger benefit in the animals treated with MSC. In or- rior effect of the MSC over the BM-MNC, including a
direct cell contribution to the vascular or cardiac tissueder to elucidate the mechanisms involved in such func-
tional improvement, we analyzed the effect of treatment and/or a positive trophic effect. In accordance with pre-
vious studies with different populations of stem cells inon angiogenesis and vasculogenesis. Capillary density
was determined 3 months after injection, by quantifying which the limited cell engraftment supports a paracrine
effect as the responsible for the functional benefit (27–the small-caliber caveolin-1-positive vessels/mm2 pres-
ent in the peri-infarct region. As depicted in Figure 9A, 29), neither BM-MNC nor MSC could be detected after
2 weeks posttransplantation, which discards a long-termonly transplantation of MSC was able to induce a signif-
icant increase in vessel count (medium: 683.9 ± 37.8 direct contribution of engrafted cells to the tissue. In the
case of the MSC, cells were detected for up to 2 weekscapillaries/mm2; BM-MNC: 705.8 ± 38.8 capillaries/mm2;
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Figure 8. Host cell proliferation. Percentage of proliferating endothelial cells (caveolin-1 positive), myofibroblasts (α-SMA posi-
tive, spindle shape), or smooth muscle cells (α-SMA positive, forming vessels) was determined by quantification of PCNA-positive
cells, within the peri-infarct and infarct areas 1 and 2 weeks after treatment (*p < 0.05 vs. medium-injected animals; **p < 0.01 vs.
medium-treated rats; #p < 0.05 BM-MNC vs. MSC: ##p < 0.01 BM-MNC vs. MSC) (A). Representative pictures of proliferating
endothelial cells (PCNA+Cav1+), myofibroblasts (PCNA+α-SMA+, spindle shape), and smooth muscle cells (PCNA+α-SMA+, ves-
sels) within the peri-infarct and the infarct areas at 1 and 2 weeks performed by confocal microscopy, are shown (arrowheads:
PCNA-positive cells) (B). GFP (Quantum Dot-655): white; caveolin-1 (Alexa-594) and α-SMA-Cy3 markers: red; PCNA (Alexa-
488): green; nuclear staining (TOPRO-3): blue. Scale bars: 15 µm.
but a direct contribution to the vascular or cardiac tissue could be explained by the differences in the protocol
model such as cell dose (five times higher in the citedwas ruled out as no differentiated cells were found.
Some other studies, but not all, have reported cardiovas- study), duration of follow-up (6 weeks vs. 3 months)
and, most importantly, timing of cell transplantation.cular differentiation of MSC (6,58) but it is still not clear
if the reported putative cardiac differentiation was due Several factors differentiate the acute versus the chronic
stage, like inflammation, fibrosis, or tissue remodelingto fusion events (5). Thereby, our results support an in-
direct trophic induction, as previously reported (28,50) [reviewed in (14,23)] and could explain the differential
effect of transplanted cells with a stronger inflamma-in several in vivo models of acute ischemia (10,15,20,
52,60,61,64) and wound healing (11). tory/angiogenic effect of transplanted mononuclear cells
in the acute stage versus a more potent effect in the tis-Differences in the cytokines expressed by each cell
population or even the longer period of time in which sue remodeling of the mesenchymal cells at the chronic
stage. Therefore, our results highlight the clinical impli-cells were detected in the heart might explain the differ-
ences observed between the effects of BM-MNC and cations for the selection of the cell type according to the
underlying disease.MSC. Interestingly, a recent comparative study per-
formed in a rodent acute model of MI (59) has shown a On the other hand, despite of the positive and promis-
ing long-term results obtained, the poor survival of thebetter functional income of BM-MNC- than MSC-
treated animals. These apparently contradictory results cells remains as the main limitation of the study. A harsh
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Figure 9. Cell transplant is associated with an increase in vasculogenesis/angiogenesis and decreased in fibrosis and infarct size.
Capillary and arterioles/arteries densities were respectively determined by quantification of the small-caliber (5–10 µm) caveolin-
1-positive capillaries/mm2 (mean ± SD) (A–D) and α-SMA-positive area (%) (mean ± SD) (E–H) in the peri-infarcted zones, 3
months after media or cell (BM-MNC or MSC) transplant. A significant increase in capillary (*p < 0.05) (A) and in arterioles/
arteries area (**p < 0.01) (E) was determined in the MSC-treated hearts (D, H) in comparison with the media-treated ones (B, F).
On the contrary, BM-MNC did not exert any effect in the capillary density (C) and, albeit, it positively affected the big vessel
revascularization (*p < 0.05) (G); this increase was significantly lower than in the MSC group (H) (**p < 0.01). Representative
images of immunofluorescence for caveolin-1 (B–D) or α-SMA (F–H) staining are shown. Vessel markers (Alexa-594): red;
nuclear staining (DAPI): blue. Morphometric analysis in serial sirius red-stained sections (I–P) showed also a significant smaller
scar size (*p < 0.05) in the left ventricles of the MSC-treated hearts in comparison with the media-treated hearts, 3 months posttrans-
plantation (I–L). Furthermore, fibrosis degree in the infarcted zone was also significantly smaller in the MSC group (*p < 0.05).
BM-MNC did not have a positive effect either in the scar size or in the fibrosis degree (M–P). Scale bars: (B–D, F–H, N–P) 100
µm; (J–L) 2.5 mm.
scar tissue environment and the immunogenicity of the ence of cells in the injured tissue. On top of the GFP
response, the MNC bone marrow fraction may containGFP are potential factors explaining the rapid cell dis-
appearance. We have to consider that, in our model, im- mature immune cells and precursors that could elicit a
stronger immune response. On the other hand, MSC hasmunosuppression with cyclosporin A inhibited T-cell-
mediated response but not monocyte/macropages action, been reported to exert an immunomodulatory effect,
which could have delayed or blunted the process (31).which can react against the GFP neoantigen as we have
demonstrated in this study and consistent with previous Improvement of cell engraftment remains a major goal
for cell therapy. In fact, several reports have shown areports (33). In the case of the BM-MNC, which elicited
a remarkable inflammatory response, the effect could be greater benefit when MSC were genetically modified by,
for example, transfection of vectors that overexpressedfaster than with the MSC, paying for the shorter pres-
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the Akt protein or the hypoxia-regulated heme oxygen- cytic, proteolytic, and inflammatory functions, while
during a later phase, monocytes promote healing via my-ase 1 (38,55) or when administered together with cyto-
kine cocktails (i.e., IGF-1) (12,17) that favored their sur- ofibroblast accumulation, angiogenesis, and deposition
of collagen (46). The potential of monocytes/macro-vival once transplanted. A different approach has used
MSC grown in vitro over matrices that can be applied phages to contribute to healing of the myocardium has
also been described in recent studies (7,11,18). Trans-to the myocardium, thereby facilitating their engraftment
(44). These strategies should be able to improve cell re- planted cells may in fact increase these processes by
stimulating the recruitment of more inflammatory cells.tention and survival or even promote the differentiation
of the cells towards desired cell phenotypes. Whether macrophage infiltration is due to the release of
growth factors or to an immune-mediated rejection pro-Another interesting finding related to the potential
mechanism of tissue repair after cell therapy was the cess as mentioned above cannot be ruled out, but in any
case may contribute to the beneficial effect. The greaterinduction of proliferation of host cells. It is conceivable
that the release of growth factors such as VEGF, HGF, macrophage infiltrate observed after BM-MNC could
also be responsible for the faster clearance of the cellsand bFGF could contribute to cell proliferation and cell
survival, consistent with previous studies with MSC (2, and should be taken into account as most of the clinical
trials performed with stem cells have been performed47,56), while the release of SDF1 (63) could stimulate
BM progenitor cell homing (1). Our study supports the with bone marrow-derived mononuclear cells.
In summary, we conclude that transplantation ofrole of transplanted cells in the in vivo induction of pro-
liferation of host cells such as endothelial and smooth MSC provide a long-term beneficial effect in cardiac
function and remodeling even when hearts are chroni-muscle cells, as previously described in vitro (28,29).
Despite cell proliferation being a short-term effect (we cally injured, despite the lack of direct contribution of
the transplanted cells. Furthermore, this is the first studycould only observed a significant proliferation for up to
2 weeks after transplant but not at 1 at 3 months), the where the potential of MSC and freshly isolated BM-
MNC has been comparatively studied in a chroniceffects were long term, as demonstrated by the increase
in angiogenesis and vasculogenesis for up to 3 months model, showing that despite some positive effect in car-
diac performance by BM-MNC, MSC had a clear supe-posttransplantation. It is important to note that no cell
proliferation was found in animals in which only media rior effect. We believe that given the demonstrated po-
tential of the MSC, it should be a population to considerwas administered, consistent which the fact that the
acute MI was induced more that 7 weeks before, a pe- for future clinical trials not only in the acute but also in
the chronic setting of the disease.riod of time in which healing of the myocardium in rats
has ensued. In addition, our results showing the induc- ACKNOWLEDGMENTS: Grant support from Ministerio de
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